KV Pharmaceutical Co. CL A News - KV.A

KV Pharmaceutical Company Completes Reorganization And Successfully Emerges From Chapter 11 With $375 Million Recapitalization

KV Pharmaceutical Company Completes Reorganization And Successfully Emerges From Chapter 11 With $375 Million Recapitalization Company Positioned...

Ther-Rx Corporation and Perrigo Company Announce the Availability of Gynazole-1® (Butoconazole Nitrate Vaginal Cream USP, 2%...

Ther-Rx Corporation and Perrigo Company Announce the Availability of Gynazole-1® (Butoconazole Nitrate Vaginal Cream USP, 2%) for...

K-V Pharmaceutical Receives Court Approval of Hologic Settlement

K-V Pharmaceutical Receives Court Approval of Hologic Settlement /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial";...

K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of P...

K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

KV Pharmaceutical Co. CL A (KV.A)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

KV.A News

KV Pharmaceutical Company Completes Reorganization And Successfully Emerges From Chapter 11 With $375 Million Recapitalization

Ther-Rx Corporation and Perrigo Company Announce the Availability of Gynazole-1® (Butoconazole Nitrate Vaginal Cream USP, 2%...

K-V Pharmaceutical Receives Court Approval of Hologic Settlement

K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of P...

K-V Pharmaceutical Use of Cash Collateral Approved by U. S. Bankruptcy Court

K-V Pharmaceutical "First Day" Motions Approved by U.S. Bankruptcy Court

K-V Pharmaceutical Class A and Class B Common Stock Begin Trading on the OTC Markets

K-V Pharmaceutical Announces Planned Transition of Trading of Class A and Class B Common Shares to the OTC Markets

K-V Pharmaceutical Company Files Voluntary Petitions for Reorganization to Restructure Financial Obligations

- Additional Proxy Soliciting Materials (definitive) (DEFA14A)

- Securities Registration Statement (S-1)

- Proxy Statement (definitive) (DEF 14A)

K-V Pharmaceutical Company Announces Additional Notification from NYSE Regarding Listing Criteria

- Amended Current report filing (8-K/A)

- Current report filing (8-K)

KV.A Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

KV Pharmaceutical Co. CL A (KV.A) News

KV Pharmaceutical Co. CL A (KV.A)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

KV.A News

KV Pharmaceutical Company Completes Reorganization And Successfully Emerges From Chapter 11 With $375 Million Recapitalization

Ther-Rx Corporation and Perrigo Company Announce the Availability of Gynazole-1® (Butoconazole Nitrate Vaginal Cream USP, 2%...

K-V Pharmaceutical Receives Court Approval of Hologic Settlement

K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of P...

K-V Pharmaceutical Use of Cash Collateral Approved by U. S. Bankruptcy Court

K-V Pharmaceutical "First Day" Motions Approved by U.S. Bankruptcy Court

K-V Pharmaceutical Class A and Class B Common Stock Begin Trading on the OTC Markets

K-V Pharmaceutical Announces Planned Transition of Trading of Class A and Class B Common Shares to the OTC Markets

K-V Pharmaceutical Company Files Voluntary Petitions for Reorganization to Restructure Financial Obligations

- Additional Proxy Soliciting Materials (definitive) (DEFA14A)

- Securities Registration Statement (S-1)

- Proxy Statement (definitive) (DEF 14A)

K-V Pharmaceutical Company Announces Additional Notification from NYSE Regarding Listing Criteria

- Amended Current report filing (8-K/A)

- Current report filing (8-K)

KV.A Discussion

Your Recent History